Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Mirum Pharmaceuticals announced FDA approval of Atebrioz for reducing new heterotopic ossification in patients 12 and older and reported positive Phase 3 AZURE-1 topline results for brelovitug in chronic hepatitis delta.Key Highlights:Original SEC Filing: Mirum Pharmaceuticals, Inc. [ MIRM ] - 8-K…
Mirum said Week 24 results in chronic hepatitis delta showed improved viral control and liver inflammation versus delayed treatment.
Mirum said brelovitug met the primary endpoint at Week 24 in Phase 3 AZURE-1 for chronic HDV, with 56% (300 mg QW) and 45% (900 mg Q4W) responders vs 0% delayed (p<0.0001). Phase 2b showed deeper viral suppression and higher ALT normalization at 48 weeks.Material DetailsContext by AI AnalystThis is…